A 51-year-old man with limb-girdle muscular dystrophy died after receiving Sarepta's experimental gene therapy and experiencing acute liver failure.

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

The firm will combine every 15 shares into one share in order to comply with Nasdaq's minimum bid price requirement.

In a final draft guidance, the committee recommended the treatment for HR-positive HER2-negative early breast cancer patients, regardless of lymph node involvement.

The privately funded basket trial makes good on its aim to enroll underrepresented groups amid a DEI-hostile federal funding ...

The firm also said it would evaluate strategic alternatives for its animal health business and close a prostate cancer vaccine trial.

For $1.8 million upfront and additional contingent and milestone payments, I-Mab gains full rights to givastomig's parental antibody.

The company will pause several gene therapy development programs, for which it intends to seek partners and other strategic alternatives.

The company, which spun out of a Korean institute, said its test has been listed at 10 leading hospitals and academic centers.